Photothermal-assisted antibacterial application of graphene oxide-Ag nanocomposites against clinically isolated multi-drug resistant
Escherichia coli.
ROYAL SOCIETY OPEN SCIENCE 2020;
7:192019. [PMID:
32874607 PMCID:
PMC7428222 DOI:
10.1098/rsos.192019]
[Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 05/05/2020] [Indexed: 05/15/2023]
Abstract
In the field of public health, treatment of multidrug-resistant (MDR) bacterial infection is a great challenge. Herein, we provide a solution to this problem with the use of graphene oxide-silver (GO-Ag) nanocomposites as antibacterial agent. Following established protocols, silver nanoparticles were grown on graphene oxide sheets. Then, a series of in vitro studies were conducted to validate the antibacterial efficiency of the GO-Ag nanocomposites against clinical MDR Escherichia coli (E. coli) strains. GO-Ag nanocomposites showed the highest antibacterial efficiency among tested antimicrobials (graphene oxide, silver nanoparticles, GO-Ag), and synergetic antibacterial effect was observed in GO-Ag nanocomposites treated group. Treatment with 14.0 µg ml-1 GO-Ag could greatly inhibit bacteria growth; remaining bacteria viabilities were 4.4% and 4.1% for MDR-1 and MDR-2 E. coli bacteria, respectively. In addition, with assistance of photothermal effect, effective sterilization could be achieved using GO-Ag nanocomposites as low as 7.0 µg ml-1. Fluorescence imaging and morphology characterization uncovered that bacteria integrity was disrupted after GO-Ag nanocomposites treatment. Cytotoxicity results of GO-Ag using human-derived cell lines (HEK 293T, Hep G2) suggested more than 80% viability remained at 7.0 µg ml-1. All the results proved that GO-Ag nanocomposites are efficient antibacterial agent against multidrug-resistant E. coli.
Collapse